Circulating tumor cells (CTCs) likely derive from clones in the primary tumor, suggesting that they can be the support of all biological tests applying to the primary cells. The new device is a single-use and low-cost innovative technology to isolate tumor cells by size on a filter without requiring a large and expansive apparatus. The System is available for cytology, cell culture, and molecular biology.
To isolate CTCs we need a tool. Once we have a reliable tool, we can address fundamental questions about clinical usefulness of CTCs.
Are CTCs representative of the primary tumor phenotypic and genotypic heterogeneity?
May CTCs characteristics be different from the primary tumor cells phenotype and genotype?
May CTCs harbor subpopulation of tumor initiating cells?
A new paradigm in drug and diagnostic development is emerging. Exciting scientific discoveries in genome biology and technology are paving the way to new product development and commercial opportunities for Rx, Dx and technology platform companies. Join us in San Francisco this August for IBC's all new Drug & Diagnostic Development event - featuring these 4 compelling conferences:
Presenter: Dr. Yvon Cayre, Professor, Department of Clinical Hematology, Hôpital Robert Debré
Dr. Yvon Cayre is currently a tenured professor of hematology at the Pierre and Marie Curie University and the clinical hematology department, at the Robert Debré hospital. He was Research Director at the French National Institute of Health (INSERM) from 1995 to 2007.
Circulating Tumors Cells as Biomarkers: Opportunities for Non-invasive Tumor Characterization and Patient Stratification in Oncology
Tuesday, April 24, 2012
2:00 pm (EDT)
3:00 pm (EDT)
After registering you will receive a confirmation email containing information about joining the Webinar.
Required: Windows® 7, Vista, XP or 2003 Server
Mac OS® X 10.5 or newer
Copyright IBC Life Sciences, a part of Informa Life Sciences Group.Phone: 800.390.4078Email: email@example.com